Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study
- PMID: 40379935
- DOI: 10.1007/s11739-025-03961-z
Serum chloride and the response to combining loop and thiazide diuretics for acute heart failure: the ALCALOTIC study
Abstract
Chloride may play an important role in the pathophysiology of heart failure (HF) as it is associated with HF prognosis and diuretic resistance. This study evaluates the diuretic response across serum chloride in patients admitted with acute heart failure (AHF) and treated with loop and thiazide diuretics. This is a subanalysis of the ALCALOTIC study, a prospective, multicentre, observational cohort study that included 665 patients admitted for AHF at 30 clinical sites in Spain. We analysed 386 patients after excluding those without baseline chloride or in-hospital weight loss data. The endpoint was in-hospital weight loss across the spectrum of baseline serum chloride. Mean age was 82 years and 59% were women. Hypochloraemia (< 96 mmol/L) and hyperchloraemia (> 106 mmol/L) were present in 59 (15%) and 65 (17%), respectively. Compared to those with chloraemia ≥ 96 mmol/L, hypochloraemia was independently associated with smaller weight loss at discharge (β coefficient - 0.78, CI 95%: - 1.53 to - 0.21, p = 0.044). Add-on thiazide to loop diuretics was associated with higher weight loss in the overall population (β Coefficient 1.23, CI 95%: 0.38 to 2.09, p = 0.005). However, a differential between-treatment association was found across serum chloride (p value for interaction = 0.020). Thiazides were associated with a greater weight loss in patients with normo- or hyperchloraemia but not in those with hypochloraemia. Hypochloraemia was associated with a worse diuretic response (measured by weight loss during hospitalization). Treatment with thiazides was associated with a better diuretic response only in patients with normo- and hyperchloraemia but not in those with hypochloraemia.
Keywords: Chloride; Diuretics; Heart failure; Thiazides.
© 2025. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Conflict of interest statement
Declarations. Conflict of interest: JN reports personal fees or advisory boards from Alleviant, AstraZeneca, Boehringer Ingelheim, Bayer, Novartis, NovoNordisk, Pfizer, Rovi, and Vifor Pharma (outside the submitted work). J.M.T. reports grants and/or personal fees from 3ive labs, Bayer, Bristol Myers Squibb, Astra Zeneca, Novartis, Cardionomic, Reprieve inc., FIRE1, W.L. Gore, Sanofi, Sequana Medical, Otsuka, Abbott, Merck, Windtree Therapeutics, Lexicon pharmaceuticals, Precardia, Relypsa, Regeneron, BD, Edwards life sciences, Lilly and Corteria pharmaceuticals. In addition, J.M.T. has a patent for Treatment of diuretic resistance issued to Yale and Corvidia Therapeutics and a patent Treatment of diuretic resistance with Reprieve inc. The rest of the authors do not have any conflicts of interest. Human and animal rights statement: The study was carried out in accordance with the Declaration of Helsinki. The study was approved by a central committee, the Clinical Research Ethics Committee of the Dr. Josep Trueta University Hospital in Girona (Spain), by the Ethics Committees of the participating centres, and by the Spanish Agency Medicines and Health Products (AEMPS in the Spanish acronym). Informed consent: The study was also registered in clinicaltrials.gov (Identifier: NCT04740242). An informed consent was obtained from all participating subjects.
References
-
- Groenewegen A, Rutten FH, Mosterd A, Hoes AW (2020) Epidemiology of heart failure. Eur J Heart Fail 22(8):1342–1356. https://doi.org/10.1002/ejhf.1858 - DOI - PubMed
-
- Chioncel O, Mebazaa A, Harjola VP, Coats AJ, Piepoli MF, Crespo-Leiro MG, Laroche C, Seferovic PM, Anker SD, Ferrari R, Ruschitzka F, Lopez-Fernandez S, Miani D, Filippatos G, Maggioni AP, ESC Heart Failure Long-Term Registry Investigators (2017) Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 19(10):1242–1254. https://doi.org/10.1002/ejhf.890 - DOI - PubMed
-
- Mullens W, Damman K, Harjola VP, Mebazaa A, Brunner-La Rocca HP, Martens P, Testani JM, Tang WHW, Orso F, Rossignol P, Metra M, Filippatos G, Seferovic PM, Ruschitzka F, Coats AJ (2019) The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21(2):137–155. https://doi.org/10.1002/ejhf.1369 - DOI - PubMed
-
- Trullàs JC, Casado J, Morales-Rull JL, Formiga F, Conde-Martel A, Quirós R, Epelde F, González-Franco Á, Manzano L, Montero-Pérez-Barquero M (2019) Prevalence and outcome of diuretic resistance in heart failure. Intern Emerg Med 14(4):529–537. https://doi.org/10.1007/s11739-018-02019-7 - DOI - PubMed
-
- Trullàs JC, Casado J, Cobo-Marcos M, Formiga F, Morales-Rull JL, Núñez J, Manzano L (2024) Combinational Diuretics in Heart Failure. Curr Heart Fail Rep 21(4):1–11. https://doi.org/10.1007/s11897-024-00659-9 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
